Change language:

Shopping cart:

0 items | $0

Diakof

Diakof
Diakof is a sugar-free cough linctus beneficial in both productive and dry cough. The mucolytic and expectorant properties reduce the viscosity of bronchial secretions and facilitate expectoration.
Diakof 100ml
PackagePer PillPriceSavingsBonusOrder
100ml × 1 bottle $36.38$36.38+ Viagra
  • INDICATIONS

    Diakof acts as a peripheral antitussive, and reduces the bronchial mucosal irritation and related bronchospasm. In addition, the anti-allergic, antimicrobial and immunostimulant properties of Diakof provide relief from cough of varied etiology.

    INSTRUCTIONS

    Take exactly as prescribed by your Health Provider.

    If you miss a dose of Diakof and you are using it regularly, use it as soon as possible. Do not use 2 doses at once.

    DOSAGE

    Please consult your Health Provider to prescribe the dosage that best suits your condition.

    STORAGE

    Store at the room temperature away from moisture and sunlight. Keep out of reach of children and pets.

     

  • There are no know precautions for using Diakof.

  • Diakof is not known to have any side effects if taken as per the prescribed dosage.

About Cialis

Cialis is an oral drug for male impotence, also known as erectile dysfunction (ED). It works by dilating blood vessels in the penis, allowing the inflow of blood needed for an erection.

Cialis causes erections only during sexual excitement. It does not work in the absence of arousal and does not increase sexual desire.

In December 2003, the Food and Drug Administration approved Cialis for sale in the United States as the third ED prescription drug pill (after sildenafil (Viagra) and vardenafil (Levitra)). Cialis 48-hour effectiveness earned it the nickname, "The Weekend Pill"; like sildenafil and vardenafil, tadalafil is recommended as an 'as needed' medication. Cialis is the only one of the three that is also offered as a once-daily medication.

Moreover, Cialis was approved in May 2009 in the United States for the treatment of pulmonary arterial hypertension and is currently under regulatory review in other regions for this condition.

$0